The pharmacogenetics of drug metabolizing enzymes in the Lebanese population

Drug Metabolism and Drug Interactions

Volumn 29, Issue 2, 2014, Pages 81-90

  Ossaily, Safaa ^a   Zgheib, Nathalie K ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

CYPs; Drug metabolizing enzymes (DMEs); Lebanon; Pharmacogenetics

Indexed keywords

ABC TRANSPORTER G1; ACENOCOUMAROL; ANTICOAGULANT AGENT; BREAST CANCER RESISTANCE PROTEIN; CALCIFEDIOL; CLOPIDOGREL; COUMARIN ANTICOAGULANT; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DOCETAXEL; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; METHOTREXATE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 6; TAMOXIFEN; WARFARIN; CYTOCHROME P450 2B6; DRUG; GLUTATHIONE TRANSFERASE; VITAMIN K EPOXIDE REDUCTASE;

ARTERY THROMBOSIS; ARTIFICIAL NEURAL NETWORK; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HIGH THROUGHPUT SEQUENCING; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEBANON; LOSS OF FUNCTION MUTATION; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION; VEIN THROMBOSIS; VITAMIN D DEFICIENCY; ARAB; DRUG INACTIVATION; GENETICS; METABOLISM;

ARABS; CYTOCHROME P-450 CYP2B6; GLUTATHIONE TRANSFERASE; HUMANS; INACTIVATION, METABOLIC; LEBANON; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; VITAMIN K EPOXIDE REDUCTASES;

EID: 84904182091     PISSN: 07925077     EISSN: 21910162     Source Type: Journal    
DOI: 10.1515/dmdi-2013-0058     Document Type: Review

References (70)

1. Tomalik-Scharte D, Lazar A, Fuhr A, Kirchheiner J. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 2008;8:4-15.
2. Mitri A, Esmerian MO, Simaan JA, Sabra R, Zghein NK. Pharmacogenetics and personalized medicine: the future for drug prescribing. J Med Liban 2010;58:101-4.
3. Djaffar-Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N. Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population. Genet Test Mol Biomark 2011;15:827-30.
4. Djaffar Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep 2011;38:5449-52.
5. Zgheib NK, Shamseddine AA, Geryess E, Tfayli A, Bazarbachi A, Salem Z, et al. Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women. Mutat Res 2013; 747-748:40-7.
6. Issa S, Zgheib NK. The role of genetic polymorphisms of N-Acetyltransferase 2 (NAT2) enzyme in the risk of bladder cancer in the Lebanese population [MS thesis]. Beirut, Lebanon: American University of Beirut, 2013.
7. Dhaini HR, Levy GN. Arylamine N-Acetyltransferase 1 (NAT1) genotypes in a Lebanese population. Pharmacogenetics 2000;10:79-83. (Pubitemid 30142816)
8. Yassine IA, Kobeissi L, Jabbour ME, Dhaini HR. N-Acetyltransferase 1 (NAT1) genotype: a risk factor for urinary bladder cancer in a Lebanese population. J Oncol 2012;2012:512976.
9. Darazy M, Balbaa M, Mugharbil A, Saeed H, Sidani H, Abdel-Razzak Z. CYP1A1, CYP2E1, and GSTM1 gene polymorphisms and susceptibility to colorectal and gastric cancer among Lebanese. Genet Test Mol Biomark 2011;15:423-9.
10. Salem AH, Yaqoob A, Ali M, Handu S, Fadel R, Abu-Hijleh M, et al. Genetic polymorphism of the glutathione S-transferase M1 and T1 genes in three distinct Arab populations. Dis Markers 2011;31:311-6.
11. Ellison CA, Abou El-Ella SS, Tawfik M, Lein PJ, Olson Jr. Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers. J Toxicol Environ Health A 2012;75:232-41.
12. Shahin MH, Khalifa SI, Gong Y, Hammad LN, Sallam MT, El Shafey M, et al. Genetic and non-genetic factors associated with warfarin dose requirements in Egyptian patient. Pharmacogenet Genom 2011;21:130-5.
13. Ismail Hamdy S, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Salah-Eldin Ahmed M, et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 2002;53:596-603. (Pubitemid 34621785)
14. Amer MA, Ghattas MH, Abo-Elmatty DM, Abou-El-Ela SH. Evaluation of glutathione S-transferase P1 genetic variants affecting type-2 diabetes susceptibility and glycemic control. Arch Med Sci 2012;8:631-6.
15. Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enany M, Moursi N, et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol 2003;55:560-9. (Pubitemid 36783197)
16. Hussein AG, Mohamed RH, Alghobashy AA. Synergism of CYP2R1 and CYP27B1 polymorphisms and susceptibility to type 1 diabetes in Egyptian children. Cell Immunol 2012;279:42-5.
17. Qumsieh R, Ali B, Abdulrazzaq Y, Osman O, Akawi N, Bastaki S. Identification of New alleles and the determination of alleles and genotypes frequencies at the CYP2D6 gene in emiratis. PLoS One 2011;6:e28943.
18. Hussain K, Salah N, Hussain S, Hussain S. Investigate the role of glutathione S transferase (GST) polymorphism in development of hypertension in UAE population. Iran Red Crescent Med J 2012;14:479-82.
19. Woolhouse NM, Qureshi MM, Bastaki SM, Patel M, Abdulrazzaq Y, Bayoumi RA. Polymorphic N-Acetyltransferase (NAT2) genotyping of Emirates. Pharmacogenetics 1997;7: 73-82. (Pubitemid 27153322)
20. Jarrar YB, Ismail S, Irshaid YM. N-Acetyltransferase-2 (NAT2) genotype frequency among Jordanian volunteers. Int J Clin Pharmacol Ther 2010;48:688-94.
21. Yousef AM, Bulatova N, Newman W, Hakooz N, Ismail S, Qusa H, et al. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol Biol Rep 2012;39:9423-33.
22. Zihlif M, Imraish A, Irshaid YM. Frequency of certain singlenucleotide polymorphisms and duplication of CYP2D6 in the Jordanian population. Genet Test Mol Biomark 2012;16:1201-5.
23. Khabaz MN. The GSTP1 Ile105Val polymorphism is not associated with susceptibility to colorectal cancer. Asian Pac J Cancer Prev 2012;13:2949-53.
24. Naffa RG, Awidi AS, Yousef AM, Ismail SI. CYP1AI, glutathione S-transferase gene polymorphisms and risk of Polycythemia vera. Cancer Epidemiol 2012;36:68-72.
25. Torkaman-Boutorabi A, Hoormand M, Naghdi N, Bakhshayes M, Milanian I. Genotype and allele frequencies N-Acetyl transferase 2 and glutathione S-transferase in the Iranian population. Clin Exp Pharmacol Physiol 2007;34:1207-11. (Pubitemid 47416363)
26. Azarpira N, Namazi S, Hendijani F, Banan M, Darai M. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran. Pharmacol Rep 2010;62:740-6.
27. Hashemi-Soteh SM, Sarzare F, Merat F, Salehifar E, Shiran MR. Frequencies of three CYP2D6 nonfunctional alleles (CYP2D63, 4, and 6) within an Iranian population (Mazandaran). Genet Test Mol Biomark 2011;15:821-5.
28. Shahriary G, Galehdari H, Jalali A, Zanganeh F, Reza Alavi S, Reza Aghanoori M. CYP2E1 5B, CYP2E1 6, CYP2E1 7B, CYP2E1 2, and CYP2E1 3 allele frequencies in Iranian populations. Asian Pac J Cancer Prev 2012;13:6505-10.
29. Moasser E, Kazemi-Nezhad SR, Saadat M, Azarpira N. Study of the association between glutathione S-transferase (GSTM1, GSTT1, GSTP1) polymorphisms with type II diabetes mellitus in southern of Iran. Mol Biol Rep 2012;39:10187-92.
30. Tanira MO, Al-Mukhaini MK, Al-Hinai AT, Al Balushi Ka, Ahmed IS. Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose. Community Genet 2007;10:32-7. (Pubitemid 46005799)
31. Tanira MO, Simsek M, Al Balushi K, Al Lawatia K, Al Barawani H, Bayoumi RA. Distribution of arylamine N-Acetyltransferase 2 (NAT2) genotypes among Omanis. J Sci Res Med Sci 2003;5:9-14.
32. Saeed H, Alanazi M, Nounou H, Shalaby M, Semlali A, Azzam N, et al. Cytochrome P450 1A1, 2E1 and GSTM1 gene polymorphisms and susceptibility to colorectal cancer in the Saudi Population. Asian Pac J Cancer Prev 2013;14:3761-68.
33. Alzahrani A, Ragia G, Hanieh H, Manolopoulos V. Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia. Biomed Res Int 2013;2013:315980.
34. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7:59-64. (Pubitemid 27153320)
35. McLellan R, Oscarson M, Seidegard J, Price Evans D, Ingelmans-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997;7:187-91. (Pubitemid 27290632)
36. Al-Dayel F, Al-Rasheed M, Ibrahim M, Bu R, Bavi P, Abubaker J, et al. Polymorphisms of drug-metabolizing enzymes CYP1A1, GSTT and GSTP contribute to the development of diffuse large B-cell lymphoma risk in the Saudi Arabian population. Leuk Lymphoma 2008;49:122-9. (Pubitemid 351146891)
37. Bu R, Gutiérrez MI, Al-Rasheed M, Belgaumi A, Bhatia K. Variable drug metabolism genes in Arab population. Pharmacogenomics J 2004;4:260-6. (Pubitemid 39136769)
38. Ouerhani S, Cherif N, Bahri I, Safra I, Menif S, Abbes S. Genetic polymorphisms of NQO1, CYP1A1 and TPMT and susceptibility to acute lymphoblastic leukemia in a Tunisian population. Mol Biol Rep 2013;40:1307-14.
39. Silan C, Tamer Dogan O, Silan F, Mutlu Kukulguven F, Asgun H, Ozdemir S, et al. The prevalence of VKORC1 1639 G > A and CYP2C9 2 3 genotypes in patients that requiring anticoagulant therapy in Turkish population. Mol Biol Rep 2012;39:11017-22.
40. Serin A, Canan H, Alper B, Gulmen M. The frequencies of mutated alleles of CYP2D6 gene in a Turkish population. Forensic Sci Int 2012;222:332-4.
41. Gönül N, Kadioglu E, Kocabas NA, Ozkaya M, Karakaya AE, Karahalil B. The role of GSTM1, GSTT1, GSTP1, and OGG1 polymorphisms in type 2 diabetes mellitus risk: a case-control study in a Turkish population. Gene 2012;505:121-7.
42. Ulusoy G, Arinç E, Adali O. Genotype and allele frequencies of polymorphic CYP2E1 in the Turkish population. Arch Toxicol 2007;81:711-8. (Pubitemid 47512602)
43. Aynacioglu AS, Cascorbi I, Mrozikiewicz PM, Roots I. Arylamine N-Acetyltransferase (NAT2) genotypes in a Turkish population. Pharmacogenetics 1997;7:327-31. (Pubitemid 27356933)
44. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012;92:414-17.
45. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine. Available at: http://www.ncbi.nlm. nih.gov/SNP/.
46. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-Acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57:581-92.
47. Haroun F, Hatoum H, Bazarbachi A, Shamseddine A, Salem Z, Taher A, et al. The role of CYP2B6 genetic polymorphisms in predicting toxicity from cyclophosphamide based therapy in Lebanese patients with breast cancer or Non-Hodgkin's Lymphoma [abstract]. Presented at: The International Union of Basic and Clinical Pharmacology 2010:17-23.
48. Esmerian M, Mitri Z, Habbal M, Geryess E, Zaatari G, Alam S, et al. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. J Clin Pharmacol 2011;51:1418-28.
49. El-Halabi M, Zgheib NK, Mansour N, Malli A, Ghaith O, Mahfouz R, et al. CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel. J Cardiovasc Pharmacol 2013;62:41-9.
50. Tfayli A, Zgheib NK, Holail Y, Habbal MZ, Halawi R, El Saghir N, et al. The influence of CYP2D6 genetic polymorphisms on variability of tamoxifen metabolism in the Lebanese breast cancer population [abstract]. Presented at: 34th San Antonio Breast Cancer (SABC) meeting; 2011:6-10.
51. Zgheib NK, Mitri Z, Geryess E, Noutsi P. Cytochrome P4502E1 (CYP2E1) genetic polymorphisms in a Lebanese population: frequency distribution and association with morbid diseases. Genet Test Mol Biomarkers 2010;14:393-7.
52. Zgheib NK, Arabi A, Mahfouz R, El-hajj Fuleihan G. CYP2R1 genetic polymorphisms are associated with lower 25-hydroxy vitamin D levels in Lebanese subjects [abstract]. Presented at: 11th EACPT Congress 2013:28-31.
53. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011;90:625-9.
54. Isma'eel H, Sakr G, Habib R, Almedawar M, Zgheib NK, Elhajj I. Improved accuracy of anticoagulant dose prediction using a pharmacogenetic and artificial neural network based method. Eur J Clin Pharmacol 2013 Dec 3. [Epub ahead of print].
55. US Food and Drug Administration. Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 020839s055lbl.pdf.
56. Yin T, Miyata T. Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res 2011;128:307-16.
57. Arabi A, El Rassi R, El-Hajj Fuleihan G. Hypovitaminosis D in developing countries -prevalence, risk factors and outcomes. Nat Rev Endocrinol 2010;6:550-61.
58. Bischoff-Ferrari H. Vitamin D -from essentiality to functionality. Int J Vitam Nutr Res 2012;82:321-6.
59. Zgheib NK, Akra M, Aridi C, Saab R, Abboud M, Mahfouz R, et al. The role of pharmacogenetics in the treatment of Lebanese patients with childhood acute lymphoblastic leukemia [abstract]. Presented at: 44th SIOP Congress; 2012:5-8.
60. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, et al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 2010;102:1003-9.
61. Afsar NA, Ufer M, Haenisch S, Remmler C, Mateen A, Usman A, et al. Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. Eur J Clin Pharmacol 2012;68:389-95.
62. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. J Am Med Assoc 2009;302:1429-36.
63. Brauch H, Chowbay B, Eccles D, Mürdter T, Saladores P, Schroth W, et al. Genetic and non-genetic determinants of tamoxifen metabolism predict drug concentrations and clinical outcomes in premenopausal patients with early breast cancer. Presented at: Annual Meeting of the American Association for Cancer Research (AACR); 2013:6-10.
64. Sissung TM, English BC, Venzon D, Figg WD, Deeken JF. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 2010;11:89-103.
65. Awada Z, Haider S, Tfayli A, Bazarbachi A, El-Saghir NS, Salem Z, et al. Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS 2013;17: 353-67.
66. Antoun J, Zgheib NK, Ashkar K. Education may improve the underutilization of genetic services by Middle Eastern primary care practitioners. Genet Test Mol Biomark 2010;14:447-54.
67. Zgheib NK, Arawi T, Mahfouz RA, Sabra R. Attitudes of health care professionals toward pharmacogenetic testing. Mol Diagn Ther 2011;15:115-22.
68. Ghaddar F, Cascorbi I, Zgheib NK. Clinical implementation of pharmacogenetics: a non-representative explorative survey to participants of WorldPharma 2010. Pharmacogenomics 2011;12:1051-9.
69. Haddow JE, Palomaki GE. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury M, Little J, Burke W, editors. Human genome epidemiology: a scientific foundation for using genetic information to improve health and prevent disease. USA: Oxford University Press, 2003: 217-33.
70. Relling MV, Klein TE. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 2011;89:464-7.